Development of a Calculated Panel Reactive Antibody Web Service with Local Frequencies for Platelet Transfusion Refractoriness Risk Stratification.
Clinical informatics
human leukocyte antigen
open source
platelet transfusion
Journal
Journal of pathology informatics
ISSN: 2229-5089
Titre abrégé: J Pathol Inform
Pays: United States
ID NLM: 101528849
Informations de publication
Date de publication:
2019
2019
Historique:
received:
13
05
2019
accepted:
01
07
2019
entrez:
30
8
2019
pubmed:
30
8
2019
medline:
30
8
2019
Statut:
epublish
Résumé
Calculated panel reactive antibody (cPRA) scoring is used to assess whether platelet refractoriness is mediated by human leukocyte antigen (HLA) antibodies in the recipient. cPRA testing uses a national sample of US kidney donors to estimate the population frequency of HLA antigens, which may be different than HLA frequencies within local platelet inventories. We aimed to determine the impact on patient cPRA scores of using HLA frequencies derived from typing local platelet donations rather than national HLA frequencies. We built an open-source web service to calculate cPRA scores based on national frequencies or custom-derived frequencies. We calculated cPRA scores for every hematopoietic stem cell transplantation (HSCT) patient at our institution based on the United Network for Organ Sharing (UNOS) frequencies and local frequencies. We compared frequencies and correlations between the calculators, segmented by gender. Finally, we put all scores into three buckets (mild, moderate, and high sensitizations) and looked at intergroup movement. 2531 patients that underwent HSCT at our institution had at least 1 antibody and were included in the analysis. Overall, the difference in medians between each group's UNOS cPRA and local cPRA was statistically significant, but highly correlated (UNOS vs. local total: 0.249 and 0.243, ρ = 0.994; UNOS vs. local female: 0.474 and 0.463, ρ = 0.987, UNOS vs. local male: 0.165 and 0.141, ρ = 0.996; cPRA scores using local frequencies were modestly but significantly different than those obtained using national HLA frequencies. We released our software as open source, so other groups can calculate cPRA scores from national or custom-derived frequencies. Further investigation is needed to determine whether a local-HLA frequency approach can improve outcomes in patients who are immune-refractory to platelets.
Sections du résumé
BACKGROUND
BACKGROUND
Calculated panel reactive antibody (cPRA) scoring is used to assess whether platelet refractoriness is mediated by human leukocyte antigen (HLA) antibodies in the recipient. cPRA testing uses a national sample of US kidney donors to estimate the population frequency of HLA antigens, which may be different than HLA frequencies within local platelet inventories. We aimed to determine the impact on patient cPRA scores of using HLA frequencies derived from typing local platelet donations rather than national HLA frequencies.
METHODS
METHODS
We built an open-source web service to calculate cPRA scores based on national frequencies or custom-derived frequencies. We calculated cPRA scores for every hematopoietic stem cell transplantation (HSCT) patient at our institution based on the United Network for Organ Sharing (UNOS) frequencies and local frequencies. We compared frequencies and correlations between the calculators, segmented by gender. Finally, we put all scores into three buckets (mild, moderate, and high sensitizations) and looked at intergroup movement.
RESULTS
RESULTS
2531 patients that underwent HSCT at our institution had at least 1 antibody and were included in the analysis. Overall, the difference in medians between each group's UNOS cPRA and local cPRA was statistically significant, but highly correlated (UNOS vs. local total: 0.249 and 0.243, ρ = 0.994; UNOS vs. local female: 0.474 and 0.463, ρ = 0.987, UNOS vs. local male: 0.165 and 0.141, ρ = 0.996;
CONCLUSIONS
CONCLUSIONS
cPRA scores using local frequencies were modestly but significantly different than those obtained using national HLA frequencies. We released our software as open source, so other groups can calculate cPRA scores from national or custom-derived frequencies. Further investigation is needed to determine whether a local-HLA frequency approach can improve outcomes in patients who are immune-refractory to platelets.
Identifiants
pubmed: 31463162
doi: 10.4103/jpi.jpi_29_19
pii: S2153-3539(22)00389-3
pmc: PMC6686574
doi:
Types de publication
Journal Article
Langues
eng
Pagination
26Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Transplantation. 1985 Mar;39(3):316-8
pubmed: 3975995
Transplant Proc. 1995 Jun;27(3):2143-4
pubmed: 7792912
Br J Haematol. 2015 Nov;171(3):297-305
pubmed: 26194869
Transfus Med Rev. 2016 Jan;30(1):1-5
pubmed: 26764124
Transplant Rev (Orlando). 2009 Oct;23(4):235-47
pubmed: 19778695
Transfusion. 1992 Jun;32(5):394-6
pubmed: 1626340
Front Immunol. 2017 May 11;8:540
pubmed: 28553286
Transplantation. 2007 Apr 15;83(7):964-72
pubmed: 17460569
Asian J Transfus Sci. 2014 Jul;8(2):126-7
pubmed: 25161354
N Engl J Med. 1969 Apr 3;280(14):735-9
pubmed: 4886455
Vox Sang. 2011 Aug;101(2):93-105
pubmed: 21535436
Am J Transplant. 2015 Dec;15(12):3194-201
pubmed: 26080906
Ann Hematol. 2018 Jan;97(1):161-167
pubmed: 29150812
Am J Transplant. 2010 Jan;10(1):26-9
pubmed: 19958328
N Engl J Med. 1997 Dec 25;337(26):1861-9
pubmed: 9417523